Biotest Facility
Private Company
Funding information not available
Overview
Biotest Facility is a specialized service provider in the diagnostics and biomarker research sector, offering end-to-end laboratory and bioinformatics services. It utilizes a suite of advanced platforms including Olink Proteomics, NanoString, Fluidigm, and digital PCR to deliver high-quality, reproducible data for its clients' research projects. The company appears to be revenue-generating, serving a client base of university hospitals and research institutions in Denmark, and is led by CEO Mogens Kruhøffer. Its strategic focus is on enabling complex, multi-omics biomarker studies for diseases like cancer, inflammation, and neurology.
Technology Platform
A multi-omics service platform utilizing Olink Proteomics (up to 3072 proteins), NanoString (gene expression), Fluidigm (qPCR, genotyping), digital PCR (QIAcuity), LC-MS/MS, and Meso Scale Discovery for comprehensive DNA, RNA, and protein analysis from complex clinical samples.
Opportunities
Risk Factors
Competitive Landscape
Biotest Facility competes with other specialized CROs and core facilities offering omics services. Its differentiation lies in its focused multi-omics portfolio, strong academic client validation, and integrated bioinformatics support within the Nordic region. Larger, global CROs offer broader services but may lack its niche technology expertise and personalized project approach.